The complexity of the TME in vivo limits the conclusions that can be drawn from in vivo models. Optimizing cell culture ...
A cancer drug developed ten years ago at UCSF can also put the brakes on one of prostate cancer's deadliest molecular tricks.
For decades microtubule-targeting agents (MTAs) have been a cornerstone of cancer treatment regimens and continue to be heavily employed as backbone chemotherapy in combination with new targeted ...
The organoid's ... Molecular Zip Code Draws ... Brain Metastases in Patients With HER2-Positive Breast Cancer Sep. 13, 2024 — A drug that delivers chemotherapy directly to tumors has shown ...
Drugs and other treatments can be quite effective at killing cancer cells, yet many fall short as they struggle to penetrate ...
South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug ...
shows promising preclinical activity in an expanded range of MSLN-positive tumor models including patient derived organoid and/or xenograft models of ovarian, pancreatic, and non-small cell lung ...
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback